scholarly journals Therapeutic efficacy of topical luliconazole versus topical ketoconazole in the treatment of pityriasis versicolor patients: a hospital based comparative study

2020 ◽  
Vol 6 (2) ◽  
pp. 248
Author(s):  
Shahid Hassan ◽  
Ashutosh Ranjan
Keyword(s):  
Comparative Study ◽  
Clinical Efficacy ◽  
Therapeutic Efficacy ◽  
Skin Lesions ◽  
Similar Efficacy ◽  
Pityriasis Versicolor ◽  
Male Population ◽  
Treatment Regimens ◽  
Mycological Examination

<p class="abstract"><strong>Background:</strong> To evaluate the clinical efficacy of 1% topical luliconazole versus 2% topical ketoconazole in pityriasis versicolor patients.</p><p class="abstract"><strong>Methods:</strong> Mycological examination of all the pityriasis versicolor patient was done by using skin scrapings were collected from the skin lesions to prepare for 10% KOH mount, which was examined under the microscope to note the findings as KOH mount positive or negative for Malassezia fungi. KOH mount positive or negative was noted at 0 days, 2 weeks and 4 weeks continued treatments with luliconazole and ketoconazole.<strong></strong></p><p class="abstract"><strong>Results:</strong> At the first days, majorities of patients 46 (92%) of luliconazole group were positive for KOH mount. At 14 days treatment with luliconazole, patients had 11 (22%) positive for KOH mount. At the 28 days treatment with luliconazole, only 2 (4%) patients were positive and most of the patients 49 (98%) were negative for KOH mount. Similarly, in ketoconazole group patients, 47 (94%) patients were positive for KOH mount in beginning of treatment. At 14 days treatment with ketoconazole 16 (32%) patients were positive and 34 (68%) patients were negative for KOH mount. And at the 28 days with treatment of ketoconazole 13 (26%) patients were positive and most of the patients 37 (74%) were negative for ketoconazole.</p><p><strong>Conclusions:</strong> Male population as well as age 26-35 years were more prone for pityriasis versicolor infection. On two weeks of treatment luliconazole and ketoconazole had near about similar efficacy against pityriasis versicolor. But, on continue 4 weeks of treatment regimens topical luliconazole had more clinically efficacious than ketoconazole against pityriasis versicolor.</p>

scholarly journals Fluconazole in the therapy of Pityriasis versicolor

2005 ◽  
pp. 283-289
Author(s):  
Mirjana Poljacki ◽  
Slobodan Stojanovic ◽  
Sinisa Tasic ◽  
Marina Jovanovic ◽  
Zoran Golusin ◽  
...  
Keyword(s):  
Single Dose ◽  
Clinical Efficacy ◽  
Clinical Examination ◽  
Therapeutic Efficacy ◽  
Pityriasis Versicolor ◽  
Mycological Examination ◽  
Clinical Healing ◽  
Systemic Application ◽  
Diagnosis Of Diseases

The authors present the results of the systemic application of flukonazole in therapy of Pityriasis versicolor. It was arranged for the total number of 38 patients, 18 females and 20 males. The diagnosis of diseases was established on the base of the clinical examination, the native mycological examination and by the using of Wood lamps. The therapy was passed by the using of 300 mg flukonazole in a single dose, once weekly, during two weeks. The following period amounted to one week after the passed therapy. The therapeutic efficacy was assessed with regard to the clinical and mycological healing. The clinical efficacy was assessed semiquantitative on the base of increasing of the percentage rates of the total score of disease that was computed by collecting of the numeric values for every clinical argument typical for the disease, and the mycological efficacy on the base of the mycological findings and the fluorescence finding after lightening with the Wood's lamp. The controlling examinations were performed on day 0, 14 and 22. The results of investigations have shown that the complete clinical healing was achieved after two weeks of therapy in 94,74%, and the mycological healing in 92,11% patients. The rate of the mycological healing was evaluated after 1 week of following period equal to the rate of the clinical healing and it was also 94,74%. The undesirable effects of the drug applications weren't by any patient.

scholarly journals The study of the effectiveness of the spray Fungin Forte in the treatment of dermatophytosis in cats

2019 ◽  
Vol 2019 (3) ◽  
pp. 30-34
Author(s):  
Лидия Куприянова ◽  
Lidiya Kupriyanova ◽  
Евгения Багринцева ◽  
Evgeniya Bagrinceva ◽  
Ольга Петрова ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Therapeutic Efficacy ◽  
Hair Growth ◽  
Skin Lesions ◽  
Local Processing ◽  
Point Scale ◽  
Complex Therapy ◽  
Oral Form

This article presents a study of the effectiveness of the spray Fungin Forte (developed by LLC API-SAN) in the complex therapy of dermatophytosis in cats on a group of 20 animals infected spontaneously. Terbinafine in oral form in tablets was used as a fungicidal preparation and Fungin Forte samples in the form of a spray were used for local processing. The criteria for clinical efficacy were the results of an examination with a planimetry, which noted a reduction and change in the affected skin lesions, a decrease in the degree of itching (using a standard 10-point scale to assess itching), erythema, peeling, hair growth, and a negative mycological study conducted on DTM environment. The total therapeutic efficacy by the thirtieth day was 95 %, which allows the use of the spray as a local fungicide.

Clinical efficacy and safety of treatment regimens for irritable bowel syndrome (a comparative study)

2016 ◽  
Vol 18 (8) ◽  
pp. 19-26 ◽  
Author(s):  
I.V. Maev ◽  
◽  
A.A. Samsonov ◽  
A.V. Yashina ◽  
D.N. Andreev ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Comparative Study ◽  
Clinical Efficacy ◽  
Efficacy And Safety ◽  
Treatment Regimens ◽  
Irritable Bowel

Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19

2020 ◽  
Vol 21 (6) ◽  
pp. 427-435 ◽  
Author(s):  
Cheng Cui ◽  
Siqi Tu ◽  
Valerie Sia Jie En ◽  
Xiaobei Li ◽  
Xueting Yao ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Clinical Efficacy ◽  
Relevant Literature ◽  
The United States ◽  
Efficacy And Safety ◽  
Open Label ◽  
Infected People ◽  
Treatment Regimens ◽  
Therapeutic Drugs

Background: As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected people is greatly increasing worldwide, the international medical situation becomes very serious. Potential therapeutic drugs, vaccine and stem cell replacement methods are emerging, so it is urgent to find specific therapeutic drugs and the best treatment regimens. After the publications on hydroxychloroquine (HCQ) with anti- SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial showed that HCQ treatment was significantly associated with reduced viral load in patients with coronavirus disease-19 (COVID-19). Meanwhile, a large prophylaxis study of HCQ sulfate for COVID-19 has been initiated in the United States. HCQ offered a promising efficacy in the treatment of COVID-19, but the optimal administration is still being explored. Methods: We used the keyword "hydroxychloroquine" to conduct a literature search in PubMed to collect relevant literature on the mechanism of action of HCQ, its clinical efficacy and safety, pharmacokinetic characteristics, precautions for clinical use and drug interactions to extract and organize information. Results: This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for HCQ sulfate. Conclusion: It has been proved that HCQ, which has an established safety profile, is effective against SARS-CoV-2 with sufficient pre-clinical rationale and evidence. Data from high-quality clinical trials are urgently needed worldwide.

scholarly journals Comparison of clinical efficacy and safety between dexmedetomidine and propofol among patients undergoing gastrointestinal endoscopy: a meta-analysis

2021 ◽  
Vol 49 (7) ◽  
pp. 030006052110327
Author(s):  
Weihua Liu ◽  
Wenli Yu ◽  
Hongli Yu ◽  
Mingwei Sheng
Keyword(s):  
Clinical Efficacy ◽  
Lower Risk ◽  
Gastrointestinal Endoscopy ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Similar Efficacy ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Inclusion Criteria ◽  
Weighted Mean

Objective To compare the clinical efficacy and safety of dexmedetomidine and propofol in patients who underwent gastrointestinal endoscopy. Methods Relevant studies comparing dexmedetomidine and propofol among patients who underwent gastrointestinal endoscopy were retrieved from databases such as PubMed, Embase, and Cochrane Library. Results Seven relevant studies (dexmedetomidine group, n = 238; propofol group, n = 239) met the inclusion criteria. There were no significant differences in the induction time (weighted mean difference [WMD] = 3.46, 95% confidence interval [CI] = −0.95–7.88, I2 = 99%) and recovery time (WMD = 2.74, 95% CI = −2.72–8.19, I2 = 98%). Subgroup analysis revealed no significant differences in the risks of hypotension (risk ratio [RR] = 0.56, 95% CI = 0.25–1.22) and nausea and vomiting (RR = 1.00, 95% CI = 0.46–2.22) between the drugs, whereas dexmedetomidine carried a lower risk of hypoxia (RR = 0.26, 95% CI = 0.11–0.63) and higher risk of bradycardia (RR = 3.01, 95% CI = 1.38–6.54). Conclusions Dexmedetomidine had similar efficacy and safety profiles as propofol in patients undergoing gastrointestinal endoscopy.

Clinical efficacy of the drug 200 mg silver proteinate in the complex therapy of acute infectious rhinitis in children, which occurred as part of an acute respiratory infection

2021 ◽  
Vol 20 (4) ◽  
pp. 88-95
Author(s):  
A. B. Kiselev ◽  
◽  
Kh. T. Abdulkerimov ◽  
N. E. Terskova ◽  
V. A. Chaukina ◽  
...  
Keyword(s):  
Comparative Study ◽  
Pharmaceutical Company ◽  
Respiratory Infection ◽  
Nasal Spray ◽  
Clinical Efficacy ◽  
Acute Respiratory Infection ◽  
Quality Of Treatment ◽  
Complex Therapy

The effectiveness of pharmacotherapy of acute infectious rhinitis in children by means of drugs from the list of medicines of the J00 Standard and in addition to this pharmacotherapy with the drug silver proteinate – 200 mg nasal spray Sialor® (manufacturer of JSC «Production Pharmaceutical Company “Obnovlenie”, Russia) was evaluated in a multicenter randomized comparative study. A higher quality of treatment was demonstrated when using 200 mg silver proteinate (Sialor®) in the form of a nasal spray in complex therapy. The article presents evidence of the feasibility of including the drug 200 mg silver proteinate in the list of medicines of the J00 Standard.

Randomized, comparative study of interferon  -1a treatment regimens in MS: The EVIDENCE Trial

Neurology ◽  
2002 ◽  
Vol 59 (10) ◽  
pp. 1496-1506 ◽  
Author(s):  
H. Panitch ◽  
D.S. Goodin ◽  
G. Francis ◽  
P. Chang ◽  
P.K. Coyle ◽  
...  
Keyword(s):  
Comparative Study ◽  
Treatment Regimens ◽  
Evidence Trial

scholarly journals Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Jörgen Elgqvist ◽  
Håkan Andersson ◽  
Holger Jensen ◽  
Helena Kahu ◽  
Sture Lindegren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cell Line ◽  
Nude Mice ◽  
Therapeutic Efficacy ◽  
Therapeutic Index ◽  
Repeated Treatment ◽  
Treatment Regimens ◽  
Potential Increase

The aim of this study was to investigate the therapeutic efficacy of -radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F labeled with the -particle emitter .Methods. Nude mice were intraperitoneally inoculated with ~ cells of the cell line NIH:OVCAR-3. Four weeks later 6 groups of animals were given F as a single or as a repeated treatment of up to 6 times ( in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled F (). Eight weeks posttreatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.Results. The tumor-free fractions (TFFs) of the animals, defined as the fraction of animals with no macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with F once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a significantly higher () TFF than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled F resulted in a TFF of zero.Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of F of up to 6 times produced increased therapeutic efficacy without observed toxicity, indicating a potential increase of the therapeutic index.

Sign in / Sign up

Export Citation Format

Share Document